AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 32867790
Drug: Oral contraceptives
RxNorm normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral contraceptives containing cyproterone acetate (CPA)
Trial: 32867790
Drug: Oral contraceptives
RxNorm normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral contraceptives containing desogestrel (DSG)
Trial: 32867790
Drug: Oral contraceptives
RxNorm normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral contraceptives containing drospirenone (DRSP)
Trial: 32867790
Drug: Oral contraceptives
RxNorm normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral contraceptives containing levonorgestrel (LNG)
Trial: 33787345
Drug: Oral prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral prednisone at a dose of 1 mg/kg/day followed by weekly stepwise tapering in steps of 10 mg/day
Trial: 32952824
Drug: Ivermectin administration
RxNorm normalized name: Ivermectin
DrugBank: Ivermectin (DB00602)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ivermectin administration over seven years
Trial: 36324229
Drug: Interferon β‐1a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon β‐1a (7.5–30 μg)
Trial: 36324229
Drug: Pegylated interferon
RxNorm normalized name: Pegylated interferon alfa-2a
DrugBank: Peginterferon alfa-2a (DB00008)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pegylated interferon β‐1a (31.25–125 μg)
Trial: 35259753
Drug: Control (Medication,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (Medication, massage, and facial exercise)
Trial: 35716984
Drug: Betadine® Surgical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Betadine® Surgical Scrub and Betadine® 5% solution (povidone‐iodine)
Trial: 38439092
Drug: Group Schema
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group Schema Therapy (GST)
Trial: 36209067
Drug: Individual Schema
RxNorm normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Individual Schema Therapy (IST)
Trial: 34600960
Drug: Cognitive Behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioral Therapy (CBT) combined with fluoxetine
Trial: 33893337
Drug: Lower PaO2/FiO2,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lower PaO2/FiO2, 2 days after treatment
Trial: 36170988
Drug: Control (monthly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (monthly text message)
Trial: 36210358
Drug: Video augmented
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Video augmented mirror therapy (MTVADG)
Trial: 36210358
Drug: Traditional mirror
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Traditional mirror therapy (TMTG)
Trial: 34371893
Drug: High flavonoid
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High flavonoid foods added to daily diet
Trial: 35239783
Drug: Caffeine (CAF,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine (CAF, 5 mg/kg)
Trial: 32801255
Drug: Restrictive transfusion
RxNorm normalized name: Pinus spp. wood destructive distillate
DrugBank: Pine tar (DB15840)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Restrictive transfusion strategy (Hb <7 g/dl)
Trial: 32801255
Drug: Liberal transfusion
RxNorm normalized name: dextromethorphan
DrugBank: Dextromethorphan (DB00514)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Liberal transfusion strategy (Hb <8 g/dl)
Trial: 33185650
Drug: Vericiguat titrated
RxNorm normalized name: Vericiguat
DrugBank: Vericiguat (DB15456)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Vericiguat titrated to 10 mg daily
Trial: 36283068
Drug: Silane application
RxNorm normalized name: silane
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Silane application with universal adhesives (Scotchbond Universal, All‐Bond Universal, G‐Premio Bond, Clearfil SE Bond)
Trial: 33136237
Drug: AAV-based gene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AAV-based gene therapy (e.g., Luxturna® - voretigene neparvovec‐rzyl)
Trial: 33136237
Drug: AAV-based therapies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AAV-based therapies
Trial: 32586939
Drug: Failure to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Failure to clear CTCs during treatment
Trial: 36240214
Drug: Medication Management
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication Management Review (MMR) service
Trial: 32379581
Drug: Ultrasound-guided PRP
RxNorm normalized name: ULTRASOUND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasound-guided PRP injection into pathological shoulder tendons targeting the supraspinatus
Trial: 32427108
Drug: iCAN-DO intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: iCAN-DO intervention (Step 1: access to psychoeducational material and peer support; Step 2: internet-based cognitive behavioral therapy)
Trial: 32714133
Drug: Regular therapies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular therapies
Trial: 34791350
Drug: 2 fractional
RxNorm normalized name: LIVER FRACTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 fractional doses of IPV (fIPV-0.1mL, intradermal) at age 6 and 14 weeks
Trial: 34791350
Drug: 2 fractional
RxNorm normalized name: LIVER FRACTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 fractional doses of IPV (fIPV-0.1mL, intradermal) at age 10 and 14 weeks
Trial: 34791350
Drug: 1 full
RxNorm normalized name: Full Marks
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 full dose of IPV (0.5mL, intramuscular) at age 14 weeks
Trial: 32744906
Drug: Oral steroids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral steroids with acupuncture
Trial: 32564093
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg oral micronized progesterone at bedtime
Trial: 35033346
Drug: Fish oil
RxNorm normalized name: Fish oil
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish oil (FO) supplementation, 60 g of product containing 30 g of FO daily
Trial: 35033346
Drug: Canola oil
RxNorm normalized name: Canola Oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Canola oil (CO) supplementation, 30 mL daily
Trial: 34925649
Drug: Ramipril (1.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ramipril (1.25 mg/d)
Trial: 34925649
Drug: Candesartan (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Candesartan (8 mg/d)
Trial: 33323306
Drug: Transcranial direct
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transcranial direct current stimulation (2 mA current, 20 minutes per session, repeated once daily for 5 consecutive days)
Trial: 33323306
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups received acetaminophen
Trial: 32074356
Drug: 2% pilocarpine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% pilocarpine ophthalmic solution (two drops)
Trial: 32074356
Drug: 2% pilocarpine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% pilocarpine ophthalmic solution (three drops)
Trial: 32404782
Drug: MF59-adjuvanted quadrivalent
RxNorm normalized name: influenza A virus (H1N1) antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MF59-adjuvanted quadrivalent influenza vaccine (aIIV4)
Trial: 32404782
Drug: Nonadjuvanted comparator
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonadjuvanted comparator influenza vaccine
Trial: 33820576
Drug: Lactobacillus rhamnosus
RxNorm normalized name: Lactobacillus Rhamnosus
DrugBank: Lacticaseibacillus rhamnosus (DB19282)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactobacillus rhamnosus GG (LGG) 1 capsule containing 1×10^10 cells twice daily (n = 44)
Trial: 33481771
Drug: 5-hydroxyindole (5-HI)
RxNorm normalized name: Butylated Hydroxyanisole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-hydroxyindole (5-HI) administered orally in rats
Trial: 33092819
Drug: Neoadjuvant chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemotherapy (NACT) with cisplatin/paclitaxel q21 followed by cold‐knife conization (CKC)
Trial: 34081314
Drug: Multi-component intervention
RxNorm normalized name: Parasedge Multi
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multi-component intervention (reverse Trendelenburg position, dysphagia screening, oral care, vaccinations)
Trial: 32898006
Drug: Systemic anticoagulation
RxNorm normalized name: CPDA-1 Anticoagulant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemic anticoagulation (SAC) therapy
Trial: 33506031
Drug: Focused Shockwave
RxNorm normalized name: AVOBENZONE 0.2 g in 1 g / BUTYLENE GLYCOL 0.1 g in 1 g TOPICAL CREAM [Focused Corrective]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Focused Shockwave Therapy (F‐SWT)
Trial: 33506031
Drug: Radial Shockwave
RxNorm normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Radial Shockwave Therapy (R‐SWT)
Trial: 37071834
Drug: Cisplatin combination
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin combination chemotherapy
Trial: 32402558
Drug: Oral sucrose
RxNorm normalized name: TootSweet 24% Oral Sucrose Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral sucrose alone (S24%)
Trial: 32526534
Drug: Collaborative Care/Stepped
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Collaborative Care/Stepped Care (CC/SC)
Trial: 34307681
Drug: Progressive Resistance
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Progressive Resistance Exercises plus Manual Therapy (PRE plus MT)
Trial: 35197068
Drug: Web-based health
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Web-based health education regarding HPV and HPV vaccines for seven days
Trial: 33226075
Drug: Housing subsidy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Housing subsidy (MTO voucher treatment)
Trial: 33123802
Drug: DNX HBr
RxNorm normalized name: Citalopram Hydrobromide
DrugBank: Citalopram (DB00215)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: DNX HBr hemihydrate tablet formulations in fed state (high fat)
Trial: 33123802
Drug: DNX HBr
RxNorm normalized name: Citalopram Hydrobromide
DrugBank: Citalopram (DB00215)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: DNX HBr monohydrate formulation
Trial: 33609343
Drug: Progressive Physical
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Progressive Physical Therapy (PPT)
Trial: 33609343
Drug: Maintenance Physical
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maintenance Physical Therapy (MPT)
Trial: 32910735
Drug: Experimental sEMG
RxNorm normalized name: Semglee
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Experimental sEMG patch
Trial: 33845988
Drug: Hyaluronic acid-enriched
RxNorm normalized name: hyaluronic acid
DrugBank: Hyaluronic acid (non-animal stabilized) (DB19175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hyaluronic acid-enriched transfer medium (EmbryoGlue, 0.5 mg/mL)
Trial: 33845988
Drug: Standard transfer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard transfer medium (supplemented G-2, 0.125 mg/mL)
Trial: 33789642
Drug: Immediate telemedicine
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Immediate telemedicine linkage to the provider and transportation to pick up induction prescription or attend intake appointment.
Trial: 33789642
Drug: Standard referral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard referral to treatment.
Trial: 33478976
Drug: Short regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Short regimen (40 mg/m2 on alternate days for 2 weeks)
Trial: 33478976
Drug: Standard regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard regimen (40 mg/m2 on alternate days for 4 weeks)
Trial: 36343085
Drug: Healbot T
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Healbot T with constraint-induced movement therapy (CIMT) mode (CIMT group; n = 10)
Trial: 35119520
Drug: Fitbit Flex™
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fitbit Flex™ and daily text messages for 12 weeks
Trial: 32355108
Drug: Extragenital screening
RxNorm normalized name: SUN PROTECTANTS/SCREENS,TOPICAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extragenital screening at both sites (rectal and pharyngeal)
Trial: 32355108
Drug: Extragenital screening
RxNorm normalized name: SUN PROTECTANTS/SCREENS,TOPICAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extragenital screening only at the rectal site
Trial: 32355108
Drug: Increasing only
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Increasing only rectal screening
Trial: 33682378
Drug: Ixekizumab (continued
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ixekizumab (continued treatment every 2 weeks)
Trial: 33682378
Drug: Placebo (withdrawal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (withdrawal of ixekizumab treatment every 2 weeks)
Trial: 33682378
Drug: Re-treatment with
RxNorm normalized name: Re-Covr
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Re-treatment with ixekizumab after relapse
Trial: 35282441
Drug: Orlistat (120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orlistat (120 mg) three times a day plus phentermine hydrochloride (37.5 mg) once daily
Trial: 35282441
Drug: Placebo three
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo three times a day plus phentermine hydrochloride (37.5 mg) once daily
Trial: 36375977
Drug: pemafibrate (0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pemafibrate (0.4 mg orally per day)
Trial: 36375977
Drug: omega-3 fatty
RxNorm normalized name: Omega-3 fatty acid
DrugBank: Omega-3 fatty acids (DB11133)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: omega-3 fatty acid ethyl esters (4 g orally per day)
Trial: 35490744
Drug: Lenabasum 20
RxNorm normalized name: Lenabasum
DrugBank: Lenabasum (DB12193)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lenabasum 20 mg daily for 28 days, then 20 mg BID for 56 days
Trial: 33346856
Drug: Patient concerns
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient concerns inventory (PCI) intervention used in outpatient clinics for one year after treatment.
Trial: 32307012
Drug: 0.3 g/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.3 g/kg NaHCO3 solution
Trial: 33884909
Drug: Meldonium trials
RxNorm normalized name: meldonium
DrugBank: Meldonium (DB13723)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meldonium trials (details on dosage and duration not available)
Trial: 32542023
Drug: Proton-pump inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Proton-pump inhibitors (PPIs)
Trial: 36531558
Drug: Isoflavone 50
RxNorm normalized name: soy isoflavone 50 mg ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isoflavone 50 mg daily for three months
Trial: 36531558
Drug: Isoflavone 50
RxNorm normalized name: soy isoflavone 50 mg ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isoflavone 50 mg daily
Trial: 33082191
Drug: Caffeine citrate
RxNorm normalized name: Caffeine Citrate
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Caffeine citrate 10 mg/kg/day
Trial: 33082191
Drug: Caffeine citrate
RxNorm normalized name: Caffeine Citrate
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Caffeine citrate 15 mg/kg/day
Trial: 34453416
Drug: Generic tadalafil
RxNorm normalized name: Tadalafil
DrugBank: Tadalafil (DB00820)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Generic tadalafil tablet (10 mg)
Trial: 34453416
Drug: Marketed tadalafil
RxNorm normalized name: Tadalafil
DrugBank: Tadalafil (DB00820)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Marketed tadalafil tablet (10 mg)
Trial: 32979645
Drug: Locoregional treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Locoregional treatments (LRTs)
Trial: 32979645
Drug: Locoregional treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Locoregional treatments (LRTs) after first progression
Trial: 34579131
Drug: Sodium Selenite
RxNorm normalized name: Sodium selenite
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Sodium Selenite Injection (SE)
Trial: 32252544
Drug: Individual Cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individual Cognitive Stimulation Therapy (iCST), 14 sessions of 45 minutes each
Trial: 35426326
Drug: Levothyroxine (L-T4)
RxNorm normalized name: L-T4
DrugBank: Levothyroxine (DB00451)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Levothyroxine (L-T4) treatment
Trial: 36152268
Drug: anti-HBc level
RxNorm normalized name: Aminosyn-HBC 7 %, Sulfite-Free
FDA approved: no
EMA approved: no
PMDA approved: no
Description: anti-HBc level < 325 IU/ml
Trial: 36152268
Drug: anti-HBc level
RxNorm normalized name: Aminosyn-HBC 7 %, Sulfite-Free
FDA approved: no
EMA approved: no
PMDA approved: no
Description: anti-HBc level ≥ 325 IU/ml
Trial: 36152268
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of anti-HBc < 325 IU/ml with HBsAg >3008 IU/mL
Trial: 36152268
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of anti-HBc < 325 IU/ml with HBcrAg ≥1790 U/ml
Trial: 34256459
Drug: Surgical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical treatment for pancreatic cancer with liver metastasis
Trial: 34256459
Drug: Systematic chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systematic chemotherapy (current standard treatment)
Trial: 33274479
Drug: CsA plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CsA plus steroids
Trial: 34629379
Drug: Bromfenac sodium
RxNorm normalized name: Bromfenac Sodium
DrugBank: Bromfenac (DB00963)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bromfenac sodium hydrate 0.1% (NSAID group) applied twice a day
Trial: 35070287
Drug: Protein supplements
RxNorm normalized name: PROTEIN SUPPLEMENTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protein supplements (20 g of protein daily)
Trial: 35070287
Drug: Placebo (zero
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (zero protein supplements)
Trial: 33706847
Drug: High-intensity cognitive
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-intensity cognitive behavioural therapy (CBT) only
Trial: 36736921
Drug: Hypofractionated radiation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypofractionated radiation therapy
Trial: 34052386
Drug: Perioperative oral
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Perioperative oral pregabalin (Lyrica, twice daily starting the evening before surgery, for a total of 4 doses)
Trial: 34052386
Drug: Single‐shot interscalene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single‐shot interscalene brachial plexus block (ISBPB, 20 ml of bupivacaine 0.25%)
Trial: 34052386
Drug: Perioperative oral
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Perioperative oral pregabalin
Trial: 32811236
Drug: 6 cycles
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 cycles of neoadjuvant chemotherapy (NACT)
Trial: 32811236
Drug: 3 cycles
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 cycles of neoadjuvant chemotherapy (NACT)
Trial: 32930131
Drug: Conventional concurrent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional concurrent chemo-radiotherapy (CCRT) - 66 Gy/33 fractions/6.5 weeks
Trial: 35938258
Drug: Levodopa/carbidopa 100/25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levodopa/carbidopa 100/25 mg three times per day for 80 weeks (early-start)
Trial: 35938258
Drug: Placebo for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for 40 weeks followed by levodopa/carbidopa 100/25 mg three times per day for 40 weeks (delayed-start)
Trial: 35938258
Drug: Early-start treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early-start treatment
Trial: 35938258
Drug: Delayed-start treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed-start treatment
Trial: 33992441
Drug: Concomitant administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Concomitant administration of CYD‐TDV and bivalent HPV vaccine
Trial: 33992441
Drug: Sequential administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sequential administration of CYD‐TDV and bivalent HPV vaccine
Trial: 32594370
Drug: Low-dose RTX
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose RTX (Protocol 1, one dose of RTX 375 mg/m2)
Trial: 32594370
Drug: Standard RTX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard RTX protocol (Protocol 2, four weekly doses of rituximab 375 mg/m2)